DelMar's lead compound VAL-083 data shows potential to be superior to current treatments in NSCLC

Clinical stage oncology company DelMar Pharmaceuticals’ lead drug compound VAL-083 has demonstrated promising results for the treatment of non-small cell lung cancer (NSCLC).

VAL-083 is an alkylating agent with a novel cytotoxic mechanism, and in previous studies has exhibited clinical activity against different tumor types including CNS tumors, solid tumors and hematologic malignancies. It is approved in China to treat chronic myelogenous leukemia.

NSCLC is usually treated with tyrosine kinase inhibitors such as gefitinib or platinum-based regimens like cisplatin. Tyrosine kinase inhibitors, however, can cause drug resistance which in turn has emerged as a significant unmet medical need, and platinum-based therapies give poor long-term prognosis.